Bayer Aktiengesellschaft

Bayer Healthcare LLC

Bayer Intellectual Property Gmbh

Bayer Schering Pharma Ag

Bayer Corporation

Bayer Healthcare Aktiengesellschaft

Adverio Pharma Gmbh

Bayer Pharma Aktiengesellschaft

Morphosys Ag

Aicuris Gmbh + Co. Kg.

Claudia Hirth-Dietrich

Andreas Knorr

Johannes-Peter Stasch

Michael Hahn

Frank Wunder

Peter Fey

Stanislav Kazda

Stefan Wohlfeil

Martin Beuck

Rudolf H Hanko

Elke Stahl

Walter Hubsch

Ulrich E Muller

Matthias Muller-Gliemann

Thomas Kramer

Jurgen Dressel

Clark Qun Pan

Hilmar Bischoff

Hans-Georg Lerchen

Klemens Lustig

Jörg Keldenich

Josef Pernerstorfer

Klaus Urbahns

Thomas Krahn

Barbara Albrecht-Küpper

Delf Schmidt

Rudolf Schohe-Loop

Markus Follmann

Alexandros Vakalopoulos

Ozkan Yalkinoglu

Michael Härter

Michael Schauer

Sabine Kraft

Barbara Krebs

Olaf Weber

Ursula Krenz

Nicole Diedrichs

Michael Woltering

Elke Dittrich-Wengenroth

Tobias Schlapp

Angela Siegling

Berthold Hinzen

Gudrun Theiss

Susanne Nikolic

Wahed Ahmed Moradi

Thomas Lampe

Gunter Schmidt

Nils Griebenow

Hans-Joachim Kabbe

Axel Kretschmer

Joerg Keldenich

Siegfried Zaiss

Paul Naab

Johannes Köbberling

Hartmut Beck

Helmut Heitzer

Marcus Bauser

Frank Süβmeier

Leila Telan

Ulf Brüggemeier

Niels Svenstrup

Hans-Dieter Volk

Barbara Albrecht

Mark Meininghaus

Peter Sandner

Georges Von Degenfeld

Elisabeth Woltering

Christiane Faeste

Matthias M uller-Gliemann

Ulrich E M Uller

J Urgen Dressel

Thomas Kr Amer

Walter H Ubsch

Elmar Reinhold Burchardt

Martina Wuttke

Petros Gatsios

Andreas M Knorr

The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs.

Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)

The present application relates to prodrug derivatives of 2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}thio)-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of cardiovascular disorders.

Dipeptoid prodrugs and their use

Dipeptoid prodrugs and the use thereof

Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.

Human TIMP-1 antibodies

The invention relates to substituted [(phenylethanoyl)amino]benzamides and methods for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of inflammatory disorders such as, for example, cutaneous, respiratory tract and cardiovascular disorders such as, for example, arteriosclerosis and coronary heart disease.

Substituted [(phenylethanoyl)amino]benzamides

This invention relates to methods for treating cardiovascular disorders selected from heart failure, thromboembolic disorders, venous diseases, and fibriotic disorders other than fibrosis of the liver, comprising administering an effective amount of a compound of formula (I) wherein the several variables are as defined in the specification and claims.

Halogen-substituted aminodicarboxylic acid derivatives

This invention relates to methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis, comprising administering an effective amount of a compound of formula (I) in which the several variables are as defined in the specification and claims.

Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis

The invention relates to substituted 2-Phenyl-3(2H)-Pyridazinones, to a method for the production thereof, and to their use as medicaments for the prophylaxis and/or treatment of diseases in humans and/or animals.

Substituted 2-phenyl-3(2h)-pyridazinones

Compounds of the general formula (I)wherein Rrepresents halogen, Rand Rrepresent H or halogen, and Rrepresents C-cycloalkyl or optionally substituted phenyl, pharamceutical compositions containing such materials, and methods of using such materials in the treatment of various diseases are disclosed and claimed.

Halogen-substituted amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases

The invention relates to compounds of the general formula (I)wherein Rrepresents H, halogen, or OCF; Rand Reach represents H or halogen; Rrepresents C-alkyl, C-cycloalkyl, CF, OCF, F, Cl, OMe, or optionally substituted phenyl; V represents O, CHO, OCF, or O&#x2014;C-alkyl-O; and W represents CHor CHCH. A process for making such compounds, pharmaceutical compositions containing them, and methods of treatment of various conditions using them are also disclosed and claimed.

Derivatives of dicarboxylic acid having pharmaceutical properties

Compounds of the general formula (I)wherein Rrepresents halogen, Rrepresent H or halogen, and Rrepresents C-cycloalkyl, C-cycloalkenyl, or optionally substituted phenyl, pharmaceutical compositions containing such material, and methods of using such materials in the treatment of various diseases are disclosed and claimed.

Side-chain halogenated amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases

This invention relates to novel potent PPAR-alpha-activating compounds which are useful in the treatment of diseases such as coronary heart disease. The invention also relates to methods of preparation of PPAR-alpha-activating compounds.

Propionic acid derivatives

The present invention relates to the use of strains of Parapoxvirus ovis as immunotherapeutic agents for immunodeficiencies of an infectious or non-infectious nature, and to the use of strains of Parapoxvirus ovis for treating tumor diseases and viral infections, and diseases which accompany them, and the use of strains of Parapoxvirus ovis for producing medicaments for use in humans and animals.

Methods of treating viral infections

Growing community of inventors

Wuppertal, Germany

Claudia Hirth-Dietrich